What clinical or logistical factors influence your choice of anti-CD38 antibody in first-line treatment of multiple myeloma?

I generally use daratumumab, because subcutaneous is more convenient for patients, and we go to once-a-month dosing much quicker with daratumumab compared to isatuximab. Once isatuximab subcutaneous is available, this advantage of daratumumab may be lost, but given comfort and familiarity with darat...

Of note, in addition to the MAIA and CEPHEUS studies, there are several similar phase 3 studies that used isatuximab, the other available anti-CD38 monoclonal antibody for MM. The IMROZ study (Facon et al., PMID 38832972) compared IsaVRd to VRd in transplant-ineligible MM and found improved response...

I agree with Dr. @Dr. First Last, Dara has been used longer and is easier to administer due to the subq formulation. Isatuximab is somewhat different than Dara and is an IV infusion. However, I have used both in 1st line and find both to be very effective when used in front-line quad induction.

In ...

Off-trial, we tend to offer anti-CD38 to all newly diagnosed patients due to the ease of administration, particularly in renal failure. Most of the time we use daratumumab, unless patients are receiving another in-clinic medication, e.g. carfilzomib. I assume isatuximab will proceed with the develop...

Excellent points by Dr. @Dr. First Last. Would add a couple more factors that could influence the choice between Daratumumab and Isatuximab,

1. Cost: This is especially important when we have 2 treatments that are roughly similar in efficacy and toxicity. However, cost changes over time and is not eas...